Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Catherine Waweru, Simarjeet Kaur, Sheetal Sharma & Namita Mishra. (2020) Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents. Current Medical Research and Opinion 36:9, pages 1481-1495.
Read now
Read now
Song Wang, Marie-Hélène Lafeuille, Patrick Lefebvre, Hela Romdhani, Bruno Emond & Mekré Senbetta. (2018) Economic burden of treatment failure in chronic lymphocytic leukemia patients. Current Medical Research and Opinion 34:6, pages 1135-1142.
Read now
Read now
Averyan Vasylyev, Valentina Molostvova, Boris A Rebrov, Janina Makarova, Andrey Zaritskey, Vadim Ptushkin, Raigul Ramazanova, Yuriy Popovych, Orest Tsyapka & Evgeny Pashanov. (2017) Standard of care and direct medical costs of the treatment of chronic lymphocytic leukemia among the adult population in Ukraine, Russia, and Kazakhstan: data from the LEUKOSPECT study. Cancer Management and Research 9, pages 387-395.
Read now
Read now
Articles from other publishers (9)
Martin Vu, Koen Degeling, Ella R. Thompson, Piers Blombery, David Westerman & Maarten J. IJzerman. (2023) Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia. Applied Health Economics and Health Policy.
Crossref
Crossref
Anuja Chatterjee, Gijs van de Wetering, Ron Goeree, Carolyn Owen, Anne Marie Desbois, Stephane Barakat, Beenish S. Manzoor & Kavita Sail. (2022) A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada. PharmacoEconomics - Open 7:2, pages 199-216.
Crossref
Crossref
Anuja ChatterjeeSheila ShapouriBeenish S ManzoorArliene RaveloKavita SailVenetia QendriGijs van de WeteringMatthew S Davids. (2021) Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States. Journal of Managed Care & Specialty Pharmacy 27:11, pages 1532-1544.
Crossref
Crossref
Qiushi ChenNitin JainTurgay AyerWilliam G. WierdaChristopher R. FlowersSusan M. O’BrienMichael J. KeatingHagop M. KantarjianJagpreet Chhatwal. (2017) Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. Journal of Clinical Oncology 35:2, pages 166-174.
Crossref
Crossref
Simon Frey, Carl R. Blankart & Tom Stargardt. (2016) Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature. PharmacoEconomics 34:5, pages 479-498.
Crossref
Crossref
Dimitrios Soudris, Sotirios Xydis, Christos Baloukas, Anastasia Hadzidimitriou, Ioanna Chouvarda, Kostas Stamatopoulos, Nicos Maglaveras, John Chang, Andreas Raptopoulos, David Manset, Barbara Pierscionek, Reem Kayyali, Nada Phillip, Tobias Becker, Katerina Vaporidi, Eumorphia Kondili, Dimitrios Georgopoulos, Lesley-Ann Sutton, Richard Rosenquist, Lydia Scarfo & Paolo Ghia. (2015) AEGLE: A big bio-data analytics framework for integrated health-care services. AEGLE: A big bio-data analytics framework for integrated health-care services.
Nicole M Engel-Nitz, Benjamin Eckert, Rui Song, Priyanka Koka, Erin M Hulbert, Jeffrey McPheeters & April Teitelbaum. (2014) Diagnostic testing managed by hematopathology specialty and other laboratories: costs and patient diagnostic outcomes. BMC Clinical Pathology 14:1.
Crossref
Crossref
K.M. Holtzer-Goor, C.A.M. Bouwmans-Frijters, M.R. Schaafsma, O. de Weerdt, P. Joosten, E.F.M. Posthuma, S. Wittebol, P.C. Huijgens, E.J.M. Mattijssen, G. Vreugdenhil, H. Visser, W.G. Peters, Z. Erjavec, P.W. Wijermans, S.M.G.J. Daenen, K.G. van der Hem, M.H.J. van Oers & C.A. Uyl-de Groot. (2014) Real-world costs of chronic lymphocytic leukaemia in the Netherlands. Leukemia Research 38:1, pages 84-90.
Crossref
Crossref
Olena Mandrik, Isaac Corro Ramos, Olga Zalis’ka, Andriy Gaisenko & Johan L. Severens. (2013) Cost for Treatment of Chronic Lymphocytic Leukemia in Specialized Institutions of Ukraine. Value in Health Regional Issues 2:2, pages 205-209.
Crossref
Crossref